home / stock / regn / regn articles

REGN Articles, Regeneron Pharmaceuticals Inc. - From 05/24/24

Stock Information
Company Name: Regeneron Pharmaceuticals Inc.
Stock Symbol: REGN
Market: NASDAQ
Website: regeneron.com
Menu
REGN REGN Quote REGN Short REGN News REGN Articles REGN Message Board
Get REGN Alerts

News, Short Squeeze, Breakout and More Instantly...
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February | Benzinga

U.S. drug wholesaler Cencora Inc (NYSE:COR), formerly AmerisourceBergen, is notifying affected individuals about their personal...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN | Benzinga

NEW YORK, May 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Reg...

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM | Benzinga

  Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm land...

Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm | Benzinga

NEW YORK, May 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigatin...
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector | Benzinga

Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct compreh...

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years | Benzinga

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 2.01% on an annualized basis producing an average ann...

Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation | Benzinga

On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported first-quarter adjusted EPS of $9.55, down 5% Y/Y, missing the consensus of $1...
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years | Benzinga

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 15.96% on an annualized basis producing an average an...

AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study | Benzinga

Thursday, AbbVie Inc (NASDAQ:ABBV) released topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Pha...

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN) | Benzinga

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Regeneron Pharmaceuti...
Previous 10 Next 10